TY - JOUR
T1 - MicroRNA Expression in Exosome Extracellular Vesicles as Targets for Personalized Medicine in Diffuse Large B Cell Lymphoma Patients with HIV Infection
AU - Cruz, Yadiel Corrales
AU - Suthumphong, Corey
AU - Caobi, Allen
AU - Andre, Mickensone
AU - Vicens, Janelle
AU - Raymond, Andrea D
AU - Ruiz, Marco
N1 - Copyright© Bentham Science Publishers; For any queries, please email at [email protected].
PY - 2024
Y1 - 2024
N2 - Extracellular Vesicles (EVs), more specifically exosomes (xEVs), have been associated with Diffuse Large B-cell Lymphoma (DLBCL). These xEVs contain a variety of biomolecules, such as proteins and nucleic acids (e.g., microRNA, LncRNA, and DNA). The expressions of these vesicles in the setting of Human Immunodeficiency Virus (HIV) have been linked to disease progression. Studies have explored the use of EVs in more practical clinical settings. Several studies have found that biomolecules within xEVs can serve to detect disease progression. The biomolecule content within xEVs is useful in prognostication and has even been associated with mechanisms of resistance for some DLBCL treatment modalities. This review article explores the role of xEV biomolecule content in DLBCL progression in the context of HIV infection and its applied use in practical disease management.
AB - Extracellular Vesicles (EVs), more specifically exosomes (xEVs), have been associated with Diffuse Large B-cell Lymphoma (DLBCL). These xEVs contain a variety of biomolecules, such as proteins and nucleic acids (e.g., microRNA, LncRNA, and DNA). The expressions of these vesicles in the setting of Human Immunodeficiency Virus (HIV) have been linked to disease progression. Studies have explored the use of EVs in more practical clinical settings. Several studies have found that biomolecules within xEVs can serve to detect disease progression. The biomolecule content within xEVs is useful in prognostication and has even been associated with mechanisms of resistance for some DLBCL treatment modalities. This review article explores the role of xEV biomolecule content in DLBCL progression in the context of HIV infection and its applied use in practical disease management.
KW - Humans
KW - MicroRNAs/metabolism
KW - HIV Infections/metabolism
KW - Lymphoma, Large B-Cell, Diffuse/metabolism
KW - Exosomes/metabolism
KW - Precision Medicine
KW - Extracellular Vesicles/metabolism
KW - Disease Progression
U2 - 10.2174/011570162X288575240821201433
DO - 10.2174/011570162X288575240821201433
M3 - Review article
C2 - 39377385
SN - 1570-162X
VL - 22
SP - 354
EP - 360
JO - Current HIV research
JF - Current HIV research
IS - 6
ER -